Theriva™ biologics presents survival outcomes data from phase 1 study evaluating vcn-01 in combination with durvalumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck at esmo congress 2023

-results show enhanced patient survival, correlating with vcn-01 mediated increases in the cps score, a key determinant of outcomes with anti-pd-(l)1 checkpoint inhibitor therapies-

TOVX Ratings Summary

TOVX Quant Ranking